Live Breaking News & Updates on Oncology Department Of The Breast Cancer Group

Stay updated with breaking news from Oncology department of the breast cancer group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Ipatasertib/Anti-HER2 Therapy Is Safe and Active in PIK3CA-Mutant, HER2+ Advanced Breast Cancer

Ipatasertib plus trastuzumab and pertuzumab as frontline maintenance therapy was effective and safe in PIK3CA-mutant, HER2-positive advanced breast cancer. ....

Comunidad Autonoma De Cataluna , Israel General , Daiichi Sankyo Astrazeneca , Mafalda Oliveira , Breast Cancer Congress , Hebron University Hospital , Breast Cancer Group , Hebron Institute Of Oncology , Oncology Department Of The Breast Cancer Group , Ayala Pharmaceuticals , Medical Oncology Department , University Hospital , Hebron Institute , Zenith Epigenetics , Cureos Science , Relay Therapeutics ,